Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-VAX in adolescents at risk of Q fever
ACTRN12622001185752Phase 4Terminated
- Sponsor
- University of Sydney
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of q fever vaccine in Q fever (2 cohorts), sponsored by University of Sydney. Primary endpoints: Solicited local reactogenicity adverse events, Solicited systemic reactogenicity adverse events and 4 more. Started Jul 2024; status: terminated.
02
Drugs
q fever vaccine
03
Conditions
Q fever
Beyond the preview
Go deeper on ACTRN12622001185752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001185752.